Trust Signals
Written by the FormBlends Medical Team. Reviewed against MEROPS database classifications, IUBMB enzyme nomenclature, and peer-reviewed biochemistry literature. No sponsored claims. Evidence grades are assigned explicitly throughout. Last reviewed 2026-05-29.
Key Takeaways
- Every peptidase is a protease, but not every protease is a peptidase. "Protease" is the umbrella term for all peptide-bond-cleaving enzymes.
- The MEROPS database (Rawlings et al., Nucleic Acids Research) classifies over 800 peptidase families into seven catalytic classes: serine, cysteine, aspartic, metallo, threonine, glutamic, and asparagine.
- Endoproteases such as trypsin cleave internal bonds; exopeptidases such as carboxypeptidase A remove single terminal amino acids. This functional split drives the sequence of protein digestion in the gut.
- Skin kallikrein-related peptidases (KLK5, KLK7) degrade topically applied peptides before penetration, a bioavailability problem almost no skincare brand discloses.
- HIV protease inhibitors, the most prescribed class of protease-targeting drugs, work by blocking an aspartic protease active site, demonstrating how precise this nomenclature must be for drug design.
Direct Answer: What Is the Difference Between a Protease and a Peptidase?
A protease is any enzyme that cleaves peptide bonds, covering both large proteins and short peptide chains. A peptidase is a subtype that preferentially acts on short oligopeptides or removes single amino acids from chain termini. All peptidases are proteases; the word protease just sets a broader boundary.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How are protease and peptidase formally defined?
- How does the MEROPS database classify these enzymes?
- What is the catalytic mechanism and where do the numbers come from?
- Evidence ledger: what do we actually know?
- Why does the distinction matter for digestion and enzyme supplements?
- What most pages get wrong: proteases in topical skincare
- The chemistry behind degradation: why peptides fall apart and how to slow it
- Head-to-head: protease vs peptidase in clinical and practical contexts
- Label and COA literacy: reading enzyme products correctly
- FAQ
- Sources
How Are Protease and Peptidase Formally Defined?
The International Union of Biochemistry and Molecular Biology (IUBMB) places all peptide-bond hydrolases under EC 3.4. Within that class, the major functional divisions are:
- Endopeptidases (EC 3.4.21 through 3.4.25 and 3.4.99): cleave internal peptide bonds in a polypeptide chain. Examples include trypsin (EC 3.4.21.4, serine protease, cleaves after Arg or Lys), pepsin (EC 3.4.23.1, aspartic protease), and MMP-1 (EC 3.4.24.7, metalloprotease).
- Exopeptidases (EC 3.4.11 through 3.4.19): remove single amino acids or dipeptides from the N- or C-terminus. Aminopeptidase N (EC 3.4.11.2) removes N-terminal residues; carboxypeptidase A (EC 3.4.17.1) removes C-terminal residues.
- Dipeptidases (EC 3.4.13.x): act only on dipeptides. These are the most restrictive peptidases and are often described as "peptidases" exclusively because they have no activity on intact proteins.
In everyday commercial use the word "protease" often means "the fraction of an enzyme blend that digests protein," while "peptidase" often specifically means exopeptidase or DPP-IV activity. That conflation creates confusion when reading supplement labels.
How Does the MEROPS Database Classify These Enzymes?
MEROPS (maintained at the Wellcome Sanger Institute, described by Rawlings, Barrett, and Bateman in successive Nucleic Acids Research database issues) is the authoritative reference. Key structural facts:
- Seven catalytic classes based on the nucleophile or general acid/base in the active site: serine (S), cysteine (C), aspartic (A), metallo (M), threonine (T), glutamic (G), and asparagine (N).
- Families within each class share statistically significant sequence similarity around the active site. Clans share structural fold even when sequence similarity is low.
- The database as of recent releases contains over 800 families. The serine protease class is the largest in terms of known enzymes in human biology.
- Importantly, MEROPS does not use "peptidase" to mean exclusively exopeptidase. Its official usage treats "peptidase" as synonymous with "protease." This is the biochemically correct but commercially confusing usage.
What Is the Catalytic Mechanism and Where Do the Numbers Come From?
The catalytic triad of serine proteases (His57-Asp102-Ser195, using chymotrypsin numbering established by Blow, Birktoft, and Hartley in 1969 work published in Nature) is the most characterized example in all of enzymology. The mechanism:
- His57 acts as a general base, abstracting a proton from Ser195.
- The activated Ser195 oxygen performs nucleophilic attack on the carbonyl carbon of the scissile peptide bond, forming a tetrahedral intermediate stabilized by the oxyanion hole (Gly193 and Ser195 backbone NH groups).
- The amine leaving group departs, an acyl-enzyme intermediate forms, and water then hydrolyzes the ester bond.
The key kinetic parameter is kcat/Km, the catalytic efficiency. For trypsin acting on small synthetic substrates, kcat/Km values are in the range of 10^6 to 10^7 M^-1 s^-1, placing it among the fastest enzymes for its substrates. Peptidases that act on dipeptides often have lower kcat values because smaller substrates form fewer productive contacts with the active site, but the numbers vary substantially by enzyme and substrate.
What this mechanism does NOT prove: High in-vitro catalytic efficiency does not mean an enzyme is clinically effective when delivered orally or topically. pH, temperature, competing substrates, inhibitors, and transit time all reduce apparent activity in biological systems.
Evidence Ledger: What Do We Actually Know?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Trypsin and chymotrypsin are serine endoproteases with established catalytic triads | X-ray crystallography, biochemical characterization (decades of replicated work) | Established mechanism | High |
| DPP-IV (dipeptidyl peptidase IV) cleaves proline-rich peptides from gluten and casein | In vitro enzyme assays, human intestinal cell studies | Positive hydrolysis | High (in vitro) |
| Oral DPP-IV enzyme supplements reduce gluten-related symptoms in non-celiac gluten sensitivity | Small human RCTs (e.g., Lerner 2017 review in Nutrients; individual trials n=20 to ~100) | Modest symptom reduction | Moderate (limited trial size) |
| Skin kallikrein-related peptidases KLK5 and KLK7 degrade applied peptides at skin surface | In vitro skin models, ex vivo human skin studies | Peptide degradation | Moderate |
| HIV protease inhibitors (aspartic protease class) reduce viral load in HIV-infected patients | Multiple large human RCTs, decades of clinical use, FDA-approved indications | Strong antiviral effect | High |
| Bromelain reduces post-surgical edema or inflammation in humans | Small RCTs, heterogeneous outcomes and dosing | Weak to modest benefit | Low to Moderate |
| Oral protease blends improve protein digestion in healthy adults | Human trials (predominantly industry-funded; e.g., DigeZyme studies) | Modestly positive | Moderate (conflict of interest risk) |
| MMP-mediated collagen degradation contributes to UV photoaging | Human skin biopsies, mechanistic studies (Fisher et al., NEJM 1997) | Established pathway | High (mechanism) |
Why Does the Distinction Matter for Digestion and Enzyme Supplements?
Protein digestion is a two-stage relay that requires both classes working in sequence:
Stage 1, stomach and upper small intestine: Pepsin (aspartic endoprotease, optimal pH roughly 1.5 to 2) and pancreatic endoproteases (trypsin, chymotrypsin, elastase) break intact dietary proteins into oligopeptide fragments of varying length. These enzymes cannot complete digestion alone.
Stage 2, brush border and cytoplasm of enterocytes: Aminopeptidases and dipeptidases (the peptidase subset) cleave the oligopeptides down to free amino acids, dipeptides, and tripeptides that can be absorbed via PepT1 and amino acid transporters. Without this step, nitrogen absorption is incomplete.
Digestive enzyme supplement labels that claim "protease activity" in Hemoglobin Units of Tyrosine (HUT) per gram are measuring endoprotease activity specifically. A product that lists DPP-IV units separately is measuring exopeptidase activity against a proline-containing substrate. Both numbers are relevant, but they measure different parts of the digestion cascade. A product high in HUT but lacking peptidase activity leaves the job half done for maximum amino acid release.
What Most Pages Get Wrong: Proteases in Topical Skincare
The omitted fact: The stratum corneum is not a passive barrier to enzymes. It contains active serine proteases, specifically kallikrein-related peptidases KLK5 and KLK7, that participate in desquamation. These same enzymes cleave topically applied peptides (such as acetyl hexapeptide-3, palmitoyl tripeptide-1) before those peptides penetrate far enough to act on fibroblasts.
Evidence basis: Studies characterizing KLK5 and KLK7 in human stratum corneum (Brattsand and Egelrud, 1999, Journal of Investigative Dermatology; subsequent work by Caubet and colleagues) established that these enzymes are active at skin surface pH (roughly 5.5) and have measurable peptidolytic activity against small peptide substrates.
What this means practically:
- Topical peptide bioavailability through intact skin is generally low, estimated in the low single-digit percent range for most small peptides in standard formulations, though precise figures vary by peptide and vehicle.
- Formulation strategies that matter: lowering vehicle pH (partially inhibits KLK activity), encapsulation in liposomes or nanoparticles, acetylation or palmitoylation of the N-terminus (reduces aminopeptidase access), and use of penetration enhancers.
- No commercial skincare brand is required to disclose how much of their active peptide survives to reach viable dermis. Independent verification of dermal delivery is rare.
This is distinct from intentional protease use in cosmetics, where keratolytic enzymes (papain, bromelain, subtilisin) are used to digest surface keratin for exfoliation. That application targets the substrate (dead keratin), not a signaling pathway.
The Chemistry Behind Degradation: Why Peptides Fall Apart and How to Slow It
A peptide applied topically or injected faces three degradation routes, each with a distinct chemical mechanism:
1. Enzymatic hydrolysis (protease/peptidase attack): As described above, serine or metallo exopeptidases cleave from termini; endoproteases cleave at specific recognition sequences (trypsin after Arg/Lys, chymotrypsin after Phe/Trp/Tyr). The rule of thumb "cap your termini" exists because aminopeptidases and carboxypeptidases require free N- or C-termini to bind. Acetylation blocks the aminopeptidase binding site by removing the positive charge of the free amine and adding steric bulk. Amidation of the C-terminus removes the carboxypeptidase recognition site.
2. Asparagine deamidation and aspartate isomerization: At physiological pH, asparagine (Asn) residues undergo spontaneous deamidation to aspartate over days to weeks, altering charge and potentially receptor binding. The rate depends on the residue following Asn; an Asn-Gly sequence deamidates fastest. This is a non-enzymatic degradation route that survives protease inhibitors.
3. Oxidation of methionine and cysteine: Methionine side chains are oxidized to methionine sulfoxide by reactive oxygen species. Cysteine thiols form disulfide bonds with other cysteines or with glutathione. In the context of the vitamin C compatibility question: ascorbic acid can reduce oxidized peptide residues in some contexts, but at high concentrations in acidic formulations it can also generate reactive oxygen intermediates via metal-catalyzed Fenton chemistry that oxidize susceptible residues. This is why mixing high-dose vitamin C with Met- or Cys-containing peptides in a single unstabilized formula is chemically risky, not merely a "rule of thumb."
Head-to-Head: Protease vs Peptidase in Key Contexts
| Context | Protease (Endoprotease) Role | Peptidase (Exopeptidase) Role | Which Matters More | Honest Caveat |
|---|---|---|---|---|
| Gut protein digestion | Breaks intact proteins to oligopeptides | Completes hydrolysis to free amino acids for absorption | Both required; neither alone is sufficient | Healthy individuals with normal pancreatic function rarely need supplements |
| Gluten/casein intolerance (non-celiac) | General protein fragmentation | DPP-IV specifically cleaves proline-rich immunogenic fragments | Peptidase (DPP-IV) for targeted symptom relief | Does NOT replace a gluten-free diet for celiac disease; evidence is modest quality |
| Topical skincare | KLK5/KLK7 (endogenous) degrade applied peptides; exogenous keratolytic enzymes exfoliate | Brush border-type exopeptidases less relevant topically | Endoproteases dominate as a barrier problem | Penetration data for most cosmetic peptides is sparse and often proprietary |
| Drug design (antiviral) | HIV aspartic protease is the drug target | Not the primary target in current antivirals | Endoprotease as drug target wins here | Resistance mutations at protease active site remain a clinical challenge |
| Wound debridement | Bromelain (cysteine endoprotease) digests necrotic tissue | Less relevant in this application | Endoprotease for debridement | Bromelain-based products like NexoBrid have regulatory approval in specific wound types; general supplement-grade bromelain evidence is weaker |
| Research peptide stability | Plasma endoproteases determine systemic half-life | Exopeptidases in blood (aminopeptidases, carboxypeptidases) contribute to rapid clearance of unmodified peptides | Both relevant; exopeptidases often faster for short peptides | Half-life data must be measured in the specific matrix (plasma, serum, tissue homogenate) to be meaningful |
Label and COA Literacy: Reading Enzyme Products Correctly
When evaluating a digestive enzyme supplement or a research enzyme preparation, these are the numbers that actually matter:
Activity units, not weight: "500 mg of protease" is nearly meaningless without an activity unit. Legitimate enzyme products state activity as HUT (Hemoglobin Units of Tyrosine, for acid proteases), FCC AP (for alkaline proteases), SAP (for acid-stable protease), or DPPIV units. These units reflect how much substrate the enzyme converts per unit time under standardized conditions.
Optimal pH range: Any COA or technical data sheet should state the pH optimum. Pepsin is active at pH 1.5 to 2; pancreatin blend enzymes function at pH 6 to 8. A protease optimized for pH 8 will have minimal activity in the stomach at pH 1.5 to 2. This matters for timing of supplement ingestion relative to meals.
Enteric coating: Acid-labile enzymes (most pancreatin-type products) should be enteric-coated or microencapsulated to survive gastric transit. An uncoated tablet of pancreatin loses the majority of its lipase activity in gastric acid and a meaningful fraction of protease activity. If the product label does not specify enteric coating and the enzymes are acid-sensitive, question the formulation.
What a degraded enzyme preparation looks like: Appearance alone is unreliable for enzyme products. Loss of activity is the key indicator and requires activity assay. However, practical warning signs include: products stored above their stated temperature range, moisture exposure (lyophilized powders clumping indicate hydration and potential denaturation), and products past their stated shelf life. Proteases can auto-digest at elevated temperatures or high moisture, reducing their own activity.
For topical peptide products: No standardized disclosure of skin penetration data is required. Look for: peptide concentration stated as a percentage or ppm, evidence of encapsulation technology, vehicle pH (should be appropriate for both stability and KLK inhibition, roughly pH 5 to 6 for most peptides), and whether the brand cites independent penetration studies rather than only in-vitro receptor binding data.
FAQ
Is a peptidase the same as a protease?
No, but all peptidases are a subset of proteases. The term protease covers all enzymes that cleave peptide bonds. Peptidase is a narrower label for proteases that act on short oligopeptides or remove single amino acids from chain ends, not full proteins.
What is the key structural difference between a protease and a peptidase?
Proteases in general can act on intact proteins and long polypeptide chains. Peptidases (exopeptidases and di/tripeptidases) preferentially act on short chains of two to about twenty residues, and many require a free amino or carboxyl terminus to bind their substrate.
Which enzymes are endoproteases versus exopeptidases?
Endoproteases such as trypsin, chymotrypsin, pepsin, and elastase cleave internal peptide bonds in a polypeptide chain. Exopeptidases such as carboxypeptidase A and aminopeptidase N remove single amino acids from the C-terminus or N-terminus respectively.
How does the MEROPS database classify these enzymes?
MEROPS classifies peptidases into clans and families based on the catalytic residue and fold. As of recent releases the database contains over 800 peptidase families distributed across serine, cysteine, aspartic, metallo, threonine, glutamic, and asparagine classes.
Why does the protease vs peptidase distinction matter for digestive enzyme supplements?
Digestive enzyme products often list both protease and peptidase activity in HUT or DPP-IV units. Proteases break large proteins into oligopeptides; peptidases then complete hydrolysis to free amino acids. Both activities are needed for full digestion, but they act at different points in the process.
What is DPP-IV and why is it listed separately on enzyme labels?
Dipeptidyl peptidase IV (DPP-IV) is a serine exopeptidase that cleaves dipeptides from the N-terminus after a proline or alanine residue. It is listed separately because it is the primary enzyme that breaks down proline-rich gluten and casein fragments, and its activity is measured in DPPIV units distinct from general HUT protease units.
Do topical peptide skincare products get degraded by skin proteases?
Yes. The stratum corneum contains serine proteases including kallikrein-related peptidases (KLK5, KLK7) that can cleave topically applied peptides before they penetrate. This is a major bioavailability concern that most skincare marketing ignores.
How are therapeutic peptides protected from protease and peptidase degradation?
Common stabilization strategies include D-amino acid substitution, N-methylation, PEGylation, cyclization, and encapsulation in nanoparticles or liposomes. Each strategy trades some receptor affinity or manufacturing complexity for increased half-life.
What does half-life mean in the context of peptide degradation by proteases?
Half-life here refers to the time for 50% of a peptide to be cleaved in a given biological compartment (plasma, gut, skin surface). Unprotected short peptides in plasma typically have half-lives measured in minutes; modified or cyclic peptides can extend this to hours or longer.
Can protease inhibitors be used clinically?
Yes. HIV protease inhibitors (ritonavir, atazanavir) are among the most successful antiviral drugs, blocking viral aspartic protease to prevent polyprotein processing. Serine protease inhibitors (such as camostat) have been studied for pancreatitis and, more recently, SARS-CoV-2 entry inhibition.
Is bromelain a protease or a peptidase?
Bromelain is classified as a cysteine endoprotease (a protease), not primarily a peptidase. It cleaves internal peptide bonds with broad specificity. It is used in supplements and some wound debridement preparations, though clinical evidence for systemic anti-inflammatory effects in humans is rated low to moderate quality.
Does protease activity in a cosmetic product break down collagen?
Intentional protease activity in cosmetics is typically used for keratolytic (exfoliating) effects on surface keratin, not dermal collagen. However, endogenous skin matrix metalloproteinases (MMPs), which are zinc-dependent proteases, do degrade collagen and elastin during UV-induced photoaging.
Sources
- Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Research. 2012;40(Database issue):D343-D350. (Successive updates published in subsequent years.)
- Blow DM, Birktoft JJ, Hartley BS. Role of a buried acid group in the mechanism of action of chymotrypsin. Nature. 1969;221(5178):337-340.
- International Union of Biochemistry and Molecular Biology (IUBMB). Enzyme Nomenclature. EC 3.4 (Peptidases). Available at: https://iubmb.org/
- Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. Journal of Biological Chemistry. 1999;274(42):30033-30040.
- Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosin by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. Journal of Investigative Dermatology. 2004;122(5):1235-1244.
- Fisher GJ, Wang ZQ, Datta SC, et al. Pathophysiology of premature skin aging induced by ultraviolet light. New England Journal of Medicine. 1997;337(20):1419-1428.
- Lerner A, Ramesh A, Matthias T. Going gluten free in non-celiac autoimmune diseases: the missing ingredient. Expert Review of Clinical Immunology. 2018;14(11):873-875. (Context for DPP-IV enzyme discussion.)
- Robinson SD, Norton RS. Conotoxin R&D: a model for the use of animal venoms in drug discovery. Advances in Biochemical Engineering/Biotechnology. 2014;135:91-120. (Peptide stability strategies context.)
- Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. American Journal of Clinical Nutrition. 2005;81(1 Suppl):317S-325S. (Background for Fenton chemistry and antioxidant interactions.)
- Flexner C. HIV drug development: the next 25 years. Nature Reviews Drug Discovery. 2007;6(12):959-966. (HIV protease inhibitor context.)
- Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid on DPP-IV activity. Diabetes/Metabolism Research and Reviews. 2011. (DPP-IV substrate specificity context.)
Footer Disclaimers
Platform: FormBlends provides educational and informational content only. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional before making any medical or supplementation decision.
Research Compound Notice: Some enzymes and peptides discussed on this page are used in research contexts and are not approved drugs in all jurisdictions. Regulatory status varies by country and application.
Results: Individual outcomes from enzyme supplements or topical peptide products vary substantially. Claims about efficacy are graded by evidence quality as indicated in the evidence ledger above. No outcome is guaranteed.
Trademark: Product names, enzyme brand names, and database names referenced on this page are the property of their respective owners. FormBlends is not affiliated with MEROPS, IUBMB, or any pharmaceutical manufacturer mentioned.